Related Experiment Videos
Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial
C Ferri1, E Marzo, G Longombardo
1Rheumatology Unit, University of Pisa, Italy.
Blood
|March 1, 1993
Summary
Interferon-alpha (IFN-alpha) therapy significantly improved clinical and serologic symptoms in patients with mixed cryoglobulinemia (MC). Treatment led to reduced cryoglobulins and improved purpura, with some patients clearing Hepatitis C virus (HCV) RNA.
Area of Science:
- Immunology
- Hepatology
- Rheumatology
Background:
- Mixed cryoglobulinemia (MC) is a systemic vasculitis often associated with Hepatitis C virus (HCV) infection.
- Current treatment options for MC can be limited, necessitating exploration of alternative therapies.
Purpose of the Study:
- To investigate the efficacy of interferon-alpha (IFN-alpha) in treating the clinical and serologic manifestations of mixed cryoglobulinemia (MC).
Main Methods:
- A randomized, crossover-controlled trial involving 26 patients with MC.
- Patients alternated between 6 months of IFN-alpha therapy and 6 months without therapy.
- IFN-alpha dosage was 2 x 10(6) IU daily for the first month, then every other day for 5 months.
Main Results:
- Significant improvement in purpura (P < .02) and serum transaminases (P < .005) was observed in 20 out of 26 patients during IFN-alpha treatment.
- Serum cryoglobulins were significantly reduced (P < .04) with IFN-alpha therapy.
- Hepatitis C virus (HCV) RNA became undetectable in 2 out of 13 patients after IFN-alpha treatment.
Conclusions:
- Interferon-alpha (IFN-alpha) demonstrates significant therapeutic potential for mixed cryoglobulinemia (MC), particularly in patients with concurrent HCV infection.
- IFN-alpha treatment led to notable improvements in clinical symptoms and serologic markers of MC.
- The study suggests IFN-alpha as a viable treatment option for MC patients who are HCV seropositive.